A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
NCT07367529 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 465
Last updated 2026-05-05
Summary
To evaluate the efficacy and safety of TQB6411 for Injection in subjects with advanced lung cancer
Conditions
Interventions
- DRUG
-
TQB6411 for Injection
TQB6411 for Injection is administered every 21 days as a treatment cycle.
Sponsors & Collaborators
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-02-26
- Primary Completion
- 2028-12-31
- Completion
- 2028-12-31
Countries
- China
Study Locations
More Related Trials
-
To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant Tumors
NCT07338838 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors
NCT06649656 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor
NCT05997342 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of TQB3455 Tablets in Subjects With Advanced Malignancies
NCT04340427 ·Status: UNKNOWN ·Phase: PHASE1
-
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors
NCT07269145 ·Status: RECRUITING ·Phase: PHASE1
-
A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors
NCT06116240 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).
NCT05346952 ·Status: UNKNOWN ·Phase: PHASE3
-
A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid Tumors
NCT06172309 ·Status: COMPLETED ·Phase: PHASE1
-
TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.
NCT06297642 ·Status: TERMINATED ·Phase: PHASE1
-
To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer.
NCT05859373 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer
NCT01631357 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors
NCT06948539 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors
NCT07251166 ·Status: RECRUITING ·Phase: PHASE1
-
Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer
NCT06141226 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
NCT05735496 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma
NCT06647836 ·Status: ENROLLING_BY_INVITATION
-
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC
NCT06328049 ·Status: RECRUITING ·Phase: PHASE2
-
TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.
NCT05718167 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics
NCT03754244 ·Status: TERMINATED ·Phase: PHASE1
-
Phase I/II Study of SCTB39G in Advanced Solid Tumours
NCT07077252 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
NCT05913089 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid
NCT03413358 ·Status: UNKNOWN ·Phase: NA
-
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
NCT07181720 ·Status: RECRUITING ·Phase: PHASE1
-
Lifei Xiaoji Wan in Treatment of Advanced NSCLC
NCT06406166 ·Status: RECRUITING ·Phase: NA
-
Autologous Tcm Cells Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC)
NCT03432156 ·Status: UNKNOWN ·Phase: PHASE2